<DOC>
	<DOCNO>NCT01457508</DOCNO>
	<brief_summary>This study assess immunogenicity safety GlaxoSmithKline ( GSK ) Biologicals ' ( formerly SB Biologicals ' ) DTPa-HBV-IPV/Hib ( Infanrix hexa™ ) vaccine compare separate administration DTPa-HBV-IPV ( Infanrix penta™ ) Hib ( Hiberix™ ) vaccine administer 3 , 5 11 ( 12 ) month age .</brief_summary>
	<brief_title>Immunogenicity Reactogenicity DTPa-HBV-IPV/Hib , Compared DTPa-HBV-IPV Hib Administered Separately</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>A male female 3 month age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject advise risk benefit study language clearly understood , performance study procedure . The following criterion check time study entry . If apply time study entry , subject must include study : Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration chronic immunosuppressant immunemodifying drug within three month vaccination . Administration vaccine foreseen study within 30 day dose study vaccine end 30 day . Previous vaccination diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib disease . History /or intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib disease infection . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine , include allergic reaction neomycin polymyxin B . Major congenital defect serious chronic illness . History seizures neurological disease study entry . Administration immunoglobulins and/or blood product since birth , plan administration study period . Acute disease time enrolment</criteria>
	<gender>All</gender>
	<minimum_age>12 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>combination vaccine</keyword>
	<keyword>DTPa-HBV-IPV</keyword>
	<keyword>Hib</keyword>
</DOC>